Minnie Kuo photo

Minnie Kuo

Chief Development Officer

Ms. Kuo joined Pliant in September 2023 as Chief Development Officer. Ms. Kuo is an experienced biotechnology and pharmaceutical executive and brings more than 20 years of multinational clinical development experience across various therapeutic areas including respiratory, oncology, neurodegenerative and inflammatory. Ms. Kuo joins Pliant from holding roles of increasing responsibilities at Vir Biotechnology, most recently serving as Senior Vice President of Translational and Clinical Development Operations. In this role, Ms. Kuo served as the operational officer to the Chief Medical Officer, overseeing business operations, clinical operations, and organizational planning across the entire clinical portfolio. Prior to Vir, Ms. Kuo held senior clinical operations roles at Nektar Therapeutics and Gilead Sciences. At Gilead, she oversaw the strategic direction of multiple compounds and indications within the company’s inflammation and hepatic portfolios. Earlier in her career, Ms. Kuo held global project management and clinical study management roles at the clinical research organization ICON and at Roche/ Genentech. Ms. Kuo received her B.A. in biochemistry and healthcare from the University of California, San Diego, and a M.S in organizational development from the University of San Francisco.

Our Team

Pliant is led by a team of world-renowned fibrosis researchers and highly experienced drug developers focused on translating science into novel therapies for patients in need.